Vulvovaginitis

Summary

Vulvovaginitis (MONDO:0007019) is a disease with 1 GWAS associations across 2 studies and 5 clinical trials. Top therapeutic interventions include butoconazole nitrate, clindamycin, and clindamycin phosphate. A subtype of vaginitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• GWAS associations: 1
• Clinical trials: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	vulvovaginitis
Mondo ID	MONDO:0007019
EFO	EFO:1001240
MeSH	D014848
DOID	DOID:2273
NCIT	C35131
SNOMED CT	53277000
UMLS	C0042998
MedGen	12129
MedDRA	10047794
Is cancer (heuristic)	no

Data availability: 1 GWAS association (2 studies).

Disease family

This is a subtype of vaginitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › reproductive system disorder › female reproductive system disorder › vaginal disorder › vaginitis › vulvovaginitis

Related subtypes (2): postmenopausal atrophic vaginitis, infective vaginitis

Subtypes (4): vulvovaginal candidiasis, vulvovaginitis, allergic seminal, herpetic vulvovaginitis, trichomonal vulvovaginitis

Genetics & variants

GWAS landscape

1 GWAS associations across 2 studies. Top hits map to 0 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs145556999	4e-08	ATP6AP1L - RPL5P16	?

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90651660	Liu TY	2025	1,941	116,027	Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.
GCST90044303	Jiang L	2021	261	247,279	A generalized linear mixed model association tool for biobank-scale data.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	1

MAF distribution

Bucket	Variants
common (>=0.05)	0
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	1

Functional consequences

Consequence	Count
intergenic_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs145556999	5	82623810	G>A,C,T		intergenic_variant	ATP6AP1L - RPL5P16	4e-08	Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 2 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Clindamycin Phosphate	Phase 3 (in late-stage trials)
Ibrexafungerp	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Fluconazole.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	2
Not specified	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00616330	PHASE3	COMPLETED	Vaginal Infection Study
NCT02971007	PHASE2	COMPLETED	Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC)
NCT03167957	PHASE2	WITHDRAWN	Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis
NCT07607470	Not specified	NOT_YET_RECRUITING	Large Algorithm Setting and Validation Study
NCT01375439	Not specified	COMPLETED	Maternal and Perinatal Outcome in Women With History of Premature Labor in Previous Pregnancy

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BUTOCONAZOLE NITRATE	4	1
CLINDAMYCIN	4	1
CLINDAMYCIN PHOSPHATE	4	1
FLUCONAZOLE	4	1
CHEMBL4791312	0	1
YEAST, DRIED	-1	1